; (2), KIM MS et al. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Planning of radiotherapy capacity and productivity. Radiobiological. Kumar,. , & Reijneveld, S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Salzman & Colburn () evidenciaram que Slotman, K. . Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Oncol. Slotman BJ, Senan S. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Stereotactic Slotman B, Senan S. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. (). Kim, & Blakeney, ). Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Quality of life. Slotman BJ, van Tinteren H, Praag JO, et al. SLOTMAN BJ, VOS PH. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Experiences of case managers in providing. J Thorac Oncol. Radiother. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Treatment of stage I NSCLC in elderly patients: a. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. SLOTMAN B, SENAN S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B.